Litifilimab Sustains Skin Clearance Through 52 Weeks in Cutaneous Lupus
Litifilimab, an investigational type I interferon-targeting biologic, maintained durable skin clearance through 52 weeks in patients with cutaneous lupus erythematosus.
Topic
Monoclonal Antibody
Topic
Monoclonal Antibody
AbbVie's zumilokibart clears Phase II with long-interval dosing signal
AbbVie reports its injectable biologic zumilokibart cleared Phase II, with a profile the company says could support quarterly or…
Sanofi-Regeneron Expand Antibody Pact to Four IL-13, IL-4 Candidates
Sanofi will pay Regeneron $1 billion up front plus up to $7 billion in milestones to co-develop four long-acting antibodies targe…